US · GH · MEDICAL - DIAGNOSTICS & RESEARCH
Guardant Health, Inc. (GH) intrinsic value and stock valuation
$145.83as of 2026-11-21 · Mkt cap 22.61B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Guardant Health, Inc. DCF and intrinsic value
InvestorsCraft values GH with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from GH’s statements →
Guardant Health, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Viatris Inc. (VTRS) $19.63
- BridgeBio Pharma, Inc. (BBIO) $76.03
- Ascendis Pharma A/S (ASND) $252.73
- Solventum Corporation (SOLV) $84.50
- Revvity, Inc. (RVTY) $145.22
- ICON Public Limited Company (ICLR) $186.71
- Encompass Health Corporation (EHC) $133.65
- Ionis Pharmaceuticals, Inc. (IONS) $26.58
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $982M | $739M | $564M | $449.5M | $373.7M |
| Operating income | -$-437.25M | -$-443.59M | -$-564.73M | -$-544.38M | -$-411M |
| Net income | -$-416.28M | -$-436.37M | -$-479.45M | -$-654.59M | -$-405.67M |
| EPSd | -$-3.32M | -$-3.55M | -$-4.28M | -$-6.41M | -$-4M |
| Operating cash flow | -$-184.76M | -$-239.86M | -$-324.98M | -$-309.46M | -$-209.02M |
| Capital expenditure | -$-48.31M | -$-35.09M | -$-20.49M | -$-77.46M | -$-75.03M |
| Free cash flow | -$-233.07M | -$-274.94M | -$-345.46M | -$-386.92M | -$-284.05M |
| Total assets | $2.01B | $1.49B | $1.79B | $1.61B | $2.2B |
| Total debt | $1.71B | $1.34B | $1.35B | $1.37B | $1.37B |
| Net debt | $1.33B | $810.5M | $220.2M | $1.23B | $881.5M |
| Total equity | -$-99.31M | -$-139.65M | $158.7M | $60.2M | $645M |
| Cash and short-term investments | $1.2B | $840M | $1.17B | $1.01B | $932.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $982M | $739M | $564M | $449.5M | $373.7M |
| Cost of revenue | $349M | $289.8M | $227.1M | $156.3M | $122.9M |
| Gross profit | $633M | $449.2M | $336.9M | $293.2M | $250.7M |
| Research and development expenses | $364.2M | $347.8M | $367.2M | $373.8M | $263.2M |
| Selling, general and administrative expenses | $706.1M | $545.1M | $451M | $463.8M | $398.5M |
| Other expenses | $0.00 | $0.00 | $83.4M | $0.00 | $0.00 |
| Operating expenses | $1.07B | $892.8M | $901.6M | $837.6M | $661.7M |
| Cost and expenses | $1.42B | $1.18B | $1.13B | $993.9M | $784.7M |
| Interest income | $34.1M | $53.7M | $35.4M | $6.07M | $3.93M |
| Interest expense | $3.9M | $2.58M | $2.58M | $2.58M | $2.58M |
| Depreciation and amortization | $39.7M | $42.4M | $42.9M | $36M | $22.3M |
| Ebitda | -$-373.91M | -$-390.12M | -$-433.31M | -$-614.91M | -$-359.62M |
| Operating income | -$-437.25M | -$-443.59M | -$-564.73M | -$-544.38M | -$-411M |
| Total other income/expenses, net | $19.7M | $8.51M | $86M | -$-109.07M | $26.5M |
| Income before tax | -$-417.54M | -$-435.09M | -$-478.76M | -$-653.45M | -$-384.47M |
| Income tax expense | -$-1.26M | $1.28M | $690K | $1.14M | $300K |
| Net income | -$-416.28M | -$-436.37M | -$-479.45M | -$-654.59M | -$-405.67M |
| Weighted average shares outstanding | $125.4M | $122.8M | $112M | $102.2M | $101.3M |
| Weighted average diluted shares outstanding | $125.4M | $122.8M | $112M | $102.2M | $101.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.2B | $840M | $1.17B | $1.01B | $932.8M |
| Net receivables | $137.9M | $110.3M | $88.8M | $97.3M | $97.7M |
| Inventory | $85.9M | $71.1M | $62M | $51.6M | $30.7M |
| Total current assets | $1.47B | $1.06B | $1.35B | $1.19B | $1.11B |
| Property, plant and equipment, net | $304.8M | $279.1M | $302.7M | $341.9M | $313.9M |
| Goodwill and intangible assets | $103.2M | $10.1M | $12.3M | $15M | $17.5M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $698M |
| Total non-current assets | $547.6M | $430.5M | $439.3M | $418.4M | $1.09B |
| Total assets | $2.01B | $1.49B | $1.79B | $1.61B | $2.2B |
| Accounts payable | $54.4M | $38.6M | $51.7M | $68.9M | $38.5M |
| Short-term debt | $27.7M | $29.2M | $28M | $21.9M | $12.9M |
| Deferred revenue | $50.8M | $35.5M | $18M | $17.4M | $11.3M |
| Total current liabilities | $302.7M | $225.6M | $205.9M | $193.2M | $194.7M |
| Long-term debt | $1.68B | $1.31B | $1.33B | $1.35B | $1.36B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.81B | $1.4B | $1.42B | $1.36B | $1.36B |
| Capital lease obligations | $206.1M | $193.5M | $213.8M | $231.9M | $238.9M |
| Total liabilities | $2.11B | $1.63B | $1.63B | $1.55B | $1.56B |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-2.99B | -$-2.58B | -$-2.14B | -$-1.66B | -$-1.01B |
| Accumulated other comprehensive income (loss) | -$-4.85M | -$-5.2M | -$-3.67M | -$-19.52M | -$-4.76M |
| Total equity | -$-99.31M | -$-139.65M | $158.7M | $60.2M | $645M |
| Total investments | $823.4M | $314.4M | $35.1M | $869.6M | $1.14B |
| Total debt | $1.71B | $1.34B | $1.35B | $1.37B | $1.37B |
| Net debt | $1.33B | $810.5M | $220.2M | $1.23B | $881.5M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-416.28M | -$-436.37M | -$-479.45M | -$-654.59M | -$-384.77M |
| Depreciation and amortization | $39.7M | $42.4M | $42.9M | $36M | $22.3M |
| Stock-based compensation | $166.2M | $140.4M | $90.8M | $94.7M | $151.5M |
| Change in working capital | -$-14.43M | -$-60.86M | $53.8M | $61.6M | -$-40.47M |
| Accounts receivable | -$-28.18M | -$-21.39M | $8.38M | $380K | -$-44.35M |
| Inventory | -$-14.79M | -$-9.13M | -$-10.35M | -$-20.93M | -$-7.96M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $60.3M | $8.64M |
| Net cash provided by operating activities | -$-184.76M | -$-239.86M | -$-324.98M | -$-309.46M | -$-209.02M |
| Investments in property, plant and equipment | -$-48.31M | -$-35.09M | -$-20.49M | -$-77.46M | -$-75.03M |
| Acquisitions, net | -$-58.99M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-627.2M | -$-261.31M | $840.3M | $149.8M | -$-63.16M |
| Common stock issued | $377.8M | $14.8M | $493.1M | $0.00 | $0.00 |
| Common stock repurchased | -$-45.01M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $671.1M | -$-1M | $477.4M | -$-189.09M | -$-66.82M |
| Net change in cash | -$-140.34M | -$-503.93M | $991.7M | -$-350.34M | -$-340.69M |
| Cash at end of period | $489.4M | $629.8M | $1.13B | $142M | $492.3M |
| Operating cash flow | -$-184.76M | -$-239.86M | -$-324.98M | -$-309.46M | -$-209.02M |
| Capital expenditure | -$-48.31M | -$-35.09M | -$-20.49M | -$-77.46M | -$-75.03M |
| Free cash flow | -$-233.07M | -$-274.94M | -$-345.46M | -$-386.92M | -$-284.05M |
Line items
Line items
Line items
About Guardant Health, Inc.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
- CEO
- Helmy Eltoukhy
- Employees
- 2.51K
- Beta
- 1.59
Explore
Frequently asked questions
What is the intrinsic value of Guardant Health, Inc. (GH)?
Guardant Health, Inc. (GH) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is GH undervalued?
GH trades at a price of $145.83 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.